Modalis Therapeutics Corporation (4883) Stock Price

Modernalis is a company specializing in gene therapy drug development, with a focus on treatments for rare diseases. The company's core technology is "non-cutting CRISPR technology (CRISPR-GNDM technology)," which enables control of gene expression without cutting DNA strands. Using this technology, the company directly controls epigenetics that cause genetic diseases and develops new therapeutic approaches.

Modernalis operates as a single business segment dedicated to gene therapy drug development. The CRISPR-GNDM technology functions as a "genetic switch" that turns genes on and off. Unlike conventional genome editing technologies, it does not involve cutting genes, making it considered highly safe. This technology can potentially provide new treatments for over 6,000 genetic diseases.

Modernalis employs two business models: a partnership model and an in-house model. In the partnership model, the company co-develops therapeutic drugs with partner companies and generates revenue through upfront payments and milestone payments. In the in-house model, the company independently selects targets and develops treatments. This approach aims for a "hybrid model" that balances early revenue generation with significant future profits.

As of the end of December 2024, Modernalis has 8 in-house pipeline programs in development. By advancing these programs, the company aims to establish licensing agreements with partners. The revenue potential of CRISPR-GNDM technology is supported by the increasing approvals of gene therapies in the United States. In particular, systemic gene therapies command high drug prices and are expected to generate significant revenue as treatments for rare diseases.

Modalis aims to contribute to the treatment of rare diseases through the development of gene therapy drugs. The company's core technology, "non-cutting CRISPR technology (CRISPR-GNDM technology)," can control gene expression without cutting genes, thereby providing new treatment approaches.

Modalis's growth strategy focuses on developing gene therapy drugs utilizing CRISPR-GNDM technology. This technology functions as a "genetic switch" that turns gene expression on and off, and is considered highly safe. Through this approach, the company aims to provide new treatment options for thousands of genetic diseases.

The company operates two business models: a partnership model and an in-house model. In the partnership model, the company co-develops therapeutic drugs with partner companies and generates revenue through contract fees and milestone payments. In the in-house model, the company independently selects targets and develops therapeutic drugs. This "hybrid model" aims to achieve both early revenue generation and substantial future profits.

As of the end of December 2024, Modalis has eight in-house model pipeline products in development. By advancing these developments, the company aims to establish licensing agreements with partners. In particular, systemic gene therapy drugs command high drug prices and are expected to generate revenue as treatments for rare diseases.